WP9 – POC platform

AP-HP will develop a POC platform to apply high sensitivity fluorescence-based detection technology to allow quantification of plasma/urinary endocan (Biothelis and AP-HP). It will exploit superparamagnetic bead technology for cell separation and multiplex immunofluorescence for the quantitation of GILZ and other intracellular targets. AP-HP and ELICE will set up a low complexity highly multiplexed molecular array using isothermal amplification with electrochemical detection of amplimer generation. This innovative technology simplifies extraction protocol in biological fluids, and will allow both the genotyping of patients on alleles informative of interventions responsiveness, and the quantification of transcripts following reverse transcription stage. It will generate signatures of interventions-regulated targets.